Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Neumora Therapeutics
Biotech
Neumora's navacaprant strikes out in phase 3 depression studies
Neumora's navacaprant has completed a clean sweep of trial misses in major depressive disorder.
Eric Sagonowsky
Jun 15, 2026 10:16am
Sage CMO steps down amid pipeline struggles—Chutes & Ladders
Mar 7, 2025 8:30am
Neumora rethinks depression drug strategy after ph. 3 failure
Mar 3, 2025 11:00am
Neumora overhauls C-suite after phase 3 flop—Chutes & Ladders
Feb 14, 2025 8:30am
Neumora's dig into phase 3 depression data disappoints analysts
Jan 15, 2025 9:35am
Neumora fails phase 3 depression trial, sending stock down 80%
Jan 2, 2025 9:17am
